Anzeige
Mehr »
Login
Samstag, 25.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 884014 | ISIN: DK0010255975 | Ticker-Symbol:
Branche
Bau/Infrastruktur
Aktienmarkt
Sonstige
1-Jahres-Chart
MT HOJGAARD HOLDING A/S Chart 1 Jahr
5-Tage-Chart
MT HOJGAARD HOLDING A/S 5-Tage-Chart
GlobeNewswire (Europe)
78 Leser
Artikel bewerten:
(0)

MT Højgaard Holding A/S: Continued profitable growth in a slowing market

Finanznachrichten News

FINANCIAL RESULTS: FIRST QUARTER OF 2024

The Danish activities continued to generate profitable growth in a slowing market in the first quarter. The winding up of the international activities progressed according to plan but weighed on the Group's overall financial performance due to losses in Greenland. MT Højgaard Holding retains its full-year forecast for 2024.

  • Consolidated revenue increased by 6% to DKK 2.3 billion, driven by developments in MT Højgaard Danmark.
  • Operating profit (EBIT) increased by 69% to DKK 94 million, corresponding to an EBIT margin increase from 2.6% to 4.1%.
  • Cash flows from operating activities were an outflow of DKK 45 million, against an inflow of DKK 44 million last year, due to losses in discontinued operations, working capital changes and payment of income tax.
  • The Group reduced its net interest-bearing debt from 534 million in first quarter of 2023 to a net interest-bearing deposit of DKK 207 million driven by strongly improved working capital and larger cash holdings.
  • Return on invested capital rose by 33.2 percentage points to 53.6%.

SOLID ORDER BOOK

The order book remained solid and widely spread across segments, project sizes and geography.

  • The order intake was DKK 1.3 billion, against DKK 4.0 billion last year. The lower level was especially due to a very large single order in the first quarter of 2023 and the postponement of projects to later in 2024 as well as a continued selective approach to a market characterised by a lower level of activity and intensified price competition.
  • Strategic construction partnerships and other collaboration projects accounted for 26% of the order intake.
  • The order book stood at DKK 12.5 billion, against DKK 15.2 billion last year. In addition, the Group had orders awarded but not yet contracted for DKK 1.4 billion, contributions from strategic construction partnerships at an estimated future value of around DKK 5.3 billion and joint ventures with a value of around DKK 950 million.

OUTLOOK FOR 2024

MT Højgaard Holding maintains its forecast of stable, profitable growth based on a solid order book and pipeline and a strong exposure to the growth segments of the market.

  • Revenue is still forecast to be in the DKK 10-10.5 billion range, or marginally higher than in 2023.
  • Operating profit (EBIT) is still expected to be in the range of DKK 400-425 million, which will be an improvement of 3%-9% relative to 2023.
  • Based on the known phasing of projects and orders, revenue and operating profit are still expected to peak in the second half of the year. About 85% of the year's expected construction revenue was contracted at the end of the first quarter.

"We had a good start to the year, recording continued growth in our Danish activities and focusing on stable production and order book execution. At the same time, we recorded strong progress in our strategic priorities with slightly better-than-expected profitability, a larger contribution from partnerships and other collaboration projects and a good momentum in winding up our international activities," says CEO Steffen Baungaard.

Contact
CEO Steffen Baungaard and CFO Rasmus Untidt may be contacted on telephone +45 31 21 68 72.

Steffen Baungaard and Rasmus Untidt will be presenting the interim report at a conference call today (16 May 2024) at 10:00 a.m. (CEST). Click here to follow the conference call live.


© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.